Table 4.
Risk factors of admission, ICU and mortality, COVID-19 infection (n = 121).
| Patient Characteristics | Admission | ICU | Death |
|---|---|---|---|
| Immunotherapy—61 | 28.0 (45.9%) | 6.0 (9.8%) | 15.0 (24.6%) ^ |
| Chemotherapy—60 | 23.0 (38.3%) | 3.0 (5.0%) | 8.0 (13.3%) ^ |
| Sociodemographics | |||
| Age (M/SD) | 64.6 (8.7) | 63.0 (11.4) | 63.0 (11.4) |
| Sex | |||
| Female | 44.0 (62.9%) | 7.0 (77.8%) | 8.0 (34.8%) |
| Male | 26.0 (51.0%) | 2.0 (22.2%) | 15.0 (65.2%) |
| Race/Ethnicity | |||
| Black | 26.0 (37.1%) | 2.0 (22.2%) | 6.0 (26.1%) |
| White | 44.0 (62.9%) | 6.0 (22.2%) | 16.0 (69.6%) |
| Asian/Latinx/Other | 0.0 (0.0%) * | 1.0 (11.11%) | 1.0 (4.35%) |
| Clinical Factors | |||
| Comorbidities | |||
| 0 | 1.0 (1.4%) | 0.0 (0.0%) | 0.0 (0.0%) |
| 1–2 | 10.0 (14.3%) | 2.0 (22.2%) | 4.0 (17.4%) |
| 3–5 | 38.0 (54.3.0%) | 5.0 (55.6%) | 10.0 (43.5%) |
| >5 | 21.0 (30.0%) | 2.0 (22.2%) | 9.0 (39.1%) |
| ECOG | 1.0 (0.8) | 1.7 (0.7) | 1.5 (0.8) |
| Symptoms at COVID-19 Diagnosis | |||
| Fever | 11.0 (21.6%) ** | 7.0 (77.8%) ** | 33.0 (33.4%) |
| Cough | 5.0 (19.2%) | 1.0 (11.1%) | 4.0 (17.4%) |
| Dyspnea | 8.0 (15.7%) | 4.0 (44.4%) * | 4.0 (17.4%) |
| PD-L1 Expression (M/SD) | 12.8 (27.0) | 19.1 (33.7) | 13.0 (23.6) |
| Immunotherapy | |||
| PD-1/PD-L1 | 31.0 (93.9%) | 6.0 (100.0%) | 14.0 (93.3%) |
| CTLA-4 | 0.0 (0.0%) | -- | 1 (6.7%) |
| Combined | 2.0 (6.1%) | -- | 0 (0.00%) |
| AST | 40.9 (48.3) | 99.1 (94.6) ** | 50.0 (65.4) |
| LDH | 341.1 (317.9) | 564.3 (436.3) | 381.1 (327.0) |
| Oxygen Use | 19.0 (27.7%) | 8.0 (88.9%) *** | 12.0 (52.2%) *** |
| Treatment | |||
| Steroids | 27.0 (34.3%) | 7.0 (77.8%) * | 10.0 (43.5%) * |
| Antiviral | 12.0 (17.1%) | 6.0 (66.7%) *** | 7.0 (30.4%) * |
| Antibiotics | 21.0 (30.0%) * | 7.0 (77.8%) *** | 8.0 (34.8%) |
* p < 0.05, ** p < 0.01, *** p < 0.001, ^ chi-square = 2.5, p = 0.2.